Trxade Group, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2020; financial statements are unaudited. The filing identifies the registrant as Trxade Group, Inc. (Nasdaq: MEDS), not Scienture Holdings, Inc.; confirm that this is the intended filing.
Business context
The company operates a pharmaceutical marketplace, a licensed wholesaler (Integra Pharma Solutions), a specialty pharmacy, and telehealth businesses. Its wholesale sales rose sharply in 2020, primarily from personal protective equipment (PPE), including masks, sanitizers, and gloves.
Financial results and position
| Metric | Three months ended September 30, 2020 | Three months ended September 30, 2019 | Nine months ended September 30, 2020 | Nine months ended September 30, 2019 |
|---|---|---|---|---|
| Revenue | $6.33 million | $2.31 million | $15.13 million | $5.74 million |
| Gross profit | $1.93 million | $1.31 million | $5.57 million | $3.62 million |
| Gross margin | 30.5% | 56.7% | 36.9% | 63.1% |
| Operating income (loss) | $146,000 | $178,000 | $(201,000) | $482,000 |
| Net income (loss) | $138,000 | $28,000 | $(224,000) | $211,000 |
- Q3 diluted earnings per share were $0.02; nine-month diluted loss per share was $0.03.
- For the first nine months, operating cash flow was negative $1.50 million, versus positive $325,000 in 2019. Investing cash outflow was $24,000; financing cash inflow was $5.30 million. Cash increased by $3.78 million.
- At September 30, cash was $6.65 million, current assets $10.64 million, current liabilities $535,000, and working capital $10.11 million. Total liabilities were $1.03 million, including $225,000 in related-party notes payable and $324,000 in lease liabilities. No off-balance-sheet arrangements were reported.
- Cash and equity increased substantially from year-end 2019, largely due to a February 2020 public stock offering that generated approximately $5.17 million net proceeds. Shares issued and outstanding rose to 8.07 million from 6.54 million at year-end 2019.
Changes and management commentary
- Q3 revenue increased 174% year over year; nine-month revenue increased 164%. Integra’s PPE-related revenue was the main driver, while Trxade platform revenue also grew.
- Higher-cost PPE sales reduced gross margin materially. Management attributed the nine-month net loss primarily to higher general and administrative expenses, especially stock-based compensation related to executive bonus shares and other awards; nine-month stock-based compensation was $1.70 million versus $168,000 a year earlier.
- Operating cash use reflected $1.08 million in inventory deposits, increased inventory purchases, and higher receivables. The company recorded a $137,000 inventory write-down.
- Management said cash on hand and anticipated operating revenue should support operations for the foreseeable future. It estimated general and administrative and working-capital requirements at approximately $6 million for October 2020 through September 2021. It also cautioned that future funding may be needed for growth or acquisitions and may not be available on favorable terms.
- COVID-19 had not materially harmed results through the filing period, according to management, but supply interruptions, delivery delays, remote-work productivity and control risks, inventory price declines, and uncertain demand could affect later results. The company said Bonum Health Hub installations were not expected to proceed before 2021 at the earliest; Bonum+ launched in August 2020.
Risks, contingencies, and unusual items
- The company disclosed approximately $1.0 million in outstanding product deposits and warned that products might not be delivered or deposits refunded. Failure to recover these amounts could result in a significant charge.
- A September 2020 federal lawsuit alleges claims related to third-party investments and seeks damages; the amount is unclear, with the company estimating approximately $450,000 in damages. The company denies merit and assesses the likelihood of a material loss as remote. A prior related case was dismissed and not appealed.
- Management concluded disclosure controls and procedures were ineffective at September 30, 2020, citing material weaknesses in written accounting/reporting policies and period-end financial reporting controls. Management said it was adding expertise and developing policies and checklists.
- The company decided not to renew one office lease, which led to a $384,000 remeasurement reduction in the related right-of-use asset and lease liability.
Most important facts to verify
- Confirm the filing matches the intended issuer: this document is for Trxade Group, Inc. (MEDS), not Scienture Holdings, Inc.
- Assess whether PPE-driven revenue and margins are sustainable as pandemic demand and supply conditions change.
- Review the recoverability and delivery status of the approximately $1.0 million in product deposits and the value and saleability of PPE inventory.
- Evaluate operating cash consumption, projected cash needs, and potential dilution if additional capital is required.
- Monitor remediation of the disclosed material weaknesses and developments in the pending lawsuit.